PIT Study Design: Phase IB/II First Line Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS Wild-Type Patients with Metastatic Colorectal Cancer

被引：0
|
作者：
Price, T. [1 ,2 ,3 ,4 ]
Rico, G. Tapia [1 ]
Williams, J. [1 ]
Yeend, S. [1 ]
Lo, L. [1 ]
Patel, D. [1 ,2 ]
Tebbutt, N. [4 ,5 ]
Shapiro, J. [4 ,6 ]
Burge, M. [4 ,7 ]
Gebski, V. [3 ]
Townsend, A. [1 ,2 ,4 ]
机构：
[1] Queen Elizabeth Hosp, Adelaide, SA, Australia
[2] Univ Adelaide, Adelaide, SA, Australia
[3] NHMRC Clin Trials Ctr, Sydney Med Sch, Sydney, NSW, Australia
[4] AGITG, Sydney, NSW, Australia
[5] Austin Hlth, Melbourne, Vic, Australia
[6] Monash Univ, Melbourne, Vic, Australia
[7] Royal Brisbane Hosp, Brisbane, Qld, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
ORAL CHEMOTHERAPEUTIC-AGENT; XENOGRAFTS; EFFICACY; TAS-102;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：72 / 72
页数：1
相关论文
共 50 条
  • [21] Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
    Patel, Shiven B.
    Gill, David
    Garrido-Laguna, Ignacio
    ONCOTARGETS AND THERAPY, 2016, 9 : 75 - 86
  • [22] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
    Tikhonova, Irina A.
    Huxley, Nicola
    Snowsill, Tristan
    Crathorne, Louise
    Varley-Campbell, Jo
    Napier, Mark
    Hoyle, Martin
    PHARMACOECONOMICS, 2018, 36 (07) : 837 - 851
  • [23] The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
    Francesca Battaglin
    Marta Schirripa
    Federica Buggin
    Filippo Pietrantonio
    Federica Morano
    Giorgia Boscolo
    Giuseppe Tonini
    Eufemia Stefania Lutrino
    Jessica Lucchetti
    Lisa Salvatore
    Alessandro Passardi
    Chiara Cremolini
    Ermenegildo Arnoldi
    Mario Scartozzi
    Nicoletta Pella
    Luca Boni
    Francesca Bergamo
    Vittorina Zagonel
    Fotios Loupakis
    Sara Lonardi
    BMC Cancer, 18
  • [24] The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
    Battaglin, Francesca
    Schirripa, Marta
    Buggin, Federica
    Pietrantonio, Filippo
    Morano, Federica
    Boscolo, Giorgia
    Tonini, Giuseppe
    Lutrino, Eufemia Stefania
    Lucchetti, Jessica
    Salvatore, Lisa
    Passardi, Alessandro
    Cremolini, Chiara
    Arnoldi, Ermenegildo
    Scartozzi, Mario
    Pella, Nicoletta
    Boni, Luca
    Bergamo, Francesca
    Zagonel, Vittorina
    Loupakis, Fotios
    Lonardi, Sara
    BMC CANCER, 2018, 18
  • [25] Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer
    Fountzilas, Christos
    Bajor, David L.
    Mukherjee, Sarbajit
    Saltzman, Joel
    Witkiewicz, Agnieszka K.
    Maguire, Orla
    Minderman, Hans
    Nambiar, Ram
    Rosenheck, Hanna R.
    Knudsen, Erik S.
    Muhitch, Jason B.
    Abrams, Scott, I
    Wang, Chong
    Hutson, Alan D.
    Attwood, Kristopher
    Hicks, Karen A.
    Jurcevic, Jennifer A.
    Kalinski, Pawel
    Iyer, Renuka
    Boland, Patrick M.
    CLINICAL CANCER RESEARCH, 2021, 27 (24) : 6726 - 6736
  • [26] Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial
    Avallone, Antonio
    Giuliani, Francesco
    De Stefano, Alfonso
    Santabarbara, Giuseppe
    Nasti, Guglielmo
    Montesarchio, Vincenzo
    Rosati, Gerardo
    Cassata, Antonino
    Leo, Silvana
    Romano, Carmela
    Tamburini, Emiliano
    Silvestro, Lucrezia
    Lotesoriere, Claudio
    Nappi, Anna
    Santini, Daniele
    Petrillo, Antonella
    Colombo, Alfredo
    Febbraro, Antonio
    Leone, Alessandra
    Mannavola, Francesco
    Laterza, Maria Maddalena
    Izzo, Francesco
    Sobrero, Alberto
    Delrio, Paolo
    Giannarelli, Diana
    Budillon, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (07)
  • [27] Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer
    Alshammari, Kanan
    Aung, Kyaw L.
    Zhang, Tong
    Razak, Albiruni R. A.
    Serra, Stefano
    Stockley, Tracy
    Wang, Lisa
    Nguyen, Jessica
    Spreafico, Anna
    Hansen, Aaron R.
    Zwir, Dave
    Siu, Lillian L.
    Bedard, Philippe L.
    CLINICAL COLORECTAL CANCER, 2021, 20 (04) : 334 - 341
  • [28] phase Ib study of irinotecan, bevacizumab and biweekly trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin: Preliminary report of MODURATE study
    Yamazaki, K.
    Masuishi, T.
    Tsushima, T.
    Muro, K.
    Yasui, H.
    Mori, K.
    Taniguchi, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S205 - S205
  • [29] A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
    Elena Elez
    Carles Pericay
    Manuel Valladares-Ayerbes
    Inmaculada Bando
    Maria Jose Safont
    Javier Gallego
    Cristina Grávalos
    Antonio Arrivi
    Alfredo Carrato
    Verónica Conde
    Maria José Ortiz
    Carlos López
    Beatriz Alonso
    Inmaculada Ruiz de Mena
    Eduardo Díaz-Rubio
    Josep Tabernero
    Enrique Aranda
    British Journal of Cancer, 2019, 121 : 378 - 383
  • [30] Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer
    Yamaguchi, Toshifumi
    Iwasa, Satoru
    Nagashima, Kengo
    Ikezawa, Nobuaki
    Hamaguchi, Tetsuya
    Shoji, Hirokazu
    Honma, Yoshitaka
    Takashima, Atsuo
    Okita, Natsuko
    Kato, Ken
    Yamada, Yasuhide
    Shimada, Yasuhiro
    ANTICANCER RESEARCH, 2016, 36 (07) : 3531 - 3536
12345